GlassScriptPhysician profile
Fady A Youssef
NPI 1386904720
$14,257.00
in general payments reported to CMS, 2019-2025
16 companies · $19.41 in 2025
The $19.41 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $879 · 2020: $57.52 · 2021: $39.56 · 2022: $6,453 · 2023: $6,617 · 2024: $191 · 2025: $19.41.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Grant: $6,250 · Travel and Lodging: $329 · Food and Beverage: $248.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Grant | $6,250.00 |
| Travel and Lodging | $328.66 |
| Food and Beverage | $248.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $12,649.58 | 2022-2024 | |
| Intuitive Surgical, INC. | $415.41 | 2022-2023 | Da Vinci Surgical System |
| Merck Sharp & Dohme LLC | $342.88 | 2019-2023 | Zerbaxa, Recarbrio |
| Chiesi USA, INC. | $250.82 | 2019 | |
| Inari Medical, INC. | $142.00 | 2019 | |
| Novartis Pharmaceuticals Corporation | $121.08 | 2019 | |
| Mylan Specialty L.P. | $103.05 | 2019 | |
| Ethicon INC. | $99.40 | 2022 | |
| Teleflex LLC | $41.16 | 2024 | Arrow |
| Olympus America INC. | $40.91 | 2023-2025 | Visiglide |
| Abiomed | $30.85 | 2019 | |
| Medtronic, INC. | $19.86 | 2021 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fady Youssef listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.